Brief: Caliway Says A Phase 2B Study For Reducing Abdominal Subcutaneous Fat Met All Main Goals

Caliway Biopharmaceuticals Co

11/12/2024 14:56

Dec 11 (Reuters) - Caliway Biopharmaceuticals Co Ltd
 6919.TW :
    * CALIWAY ANNOUNCES SUCCESSFUL STUDY RESULTS FROM CBL-0204,
A
CBL-514 PHASE 2B STUDY FOR REDUCING ABDOMINAL SUBCUTANEOUS FAT,
MET ALL PRIMARY AND SECONDARY EFFICACY ENDPOINTS
    * CALIWAY - COMPARED TO PLACEBO GROUP,  CBL-514 REDUCES OVER
30%
OF ABDOMINAL FAT THICKNESS IN PP POPULATION

Source text:  ID:nPn2wY5fDa 
Further company coverage:  6919.TW 

 ((Reuters.Briefs@thomsonreuters.com;))